Prevention

Using a unique approach of targeting the stalk of the hemagglutinin, investigators are taking steps toward developing a universal influenza vaccine candidate.

Gregory Felzien, MD, AAHIVS, discusses barriers to HIV care, particularly in neglected rural areas.

Anandi Sheth, MD, MSc, summarizes her presentation on HIV prevention in women and discusses the need for more women in pre-exposure prophylaxis research.

The Closing Plenary of IDWeek 2019 discussed the challenges of vaccination and the optimism that we may be on the path to eradicating some global infectious diseases.

The mobile unit provided services to 229 clients from October 2018 to April 2019, 168 (73.7%) of whom sought PrEP.

The NFID released data revealing that only 52% of adults in the United States plan to get vaccinated against the flu this season.

A human vaccine could reach clinical trials in 2 years, the lead researcher told Contagion®.

The vaccine, manufactured by Johnson & Johnson, is administered in 2 doses, 56 days apart and will be used in areas that are not experiencing active transmission.

A National Influenza Vaccine Task Force has been established, which will develop a 5-year plan to promote new vaccine manufacturing technology and to accelerate the development of a universal flu vaccine.

Touring production called “Eureka Day” depicts parents of schoolchildren arguing both sides—but definitely has a point of view.

In the doxycycline as PrEP arm, there was a 73% reduction (p = .02) in syphilis, Neisseria gonorrhoeae, and Chlamydia trachomatis infections.

Being geographically close a measles outbreak could change the way individuals feel about getting vaccinated against the disease.

As the summer comes to a close, our editorial team is looking back at the top FDA approvals of 2019 to date and looking ahead at what is left on the docket this year.

Investigators with Seqirus presented findings from a handful of studies on a MF59 adjuvanted influenza vaccine at the Options for the Control of Influenza (OPTIONS X) Conference in Singapore.

As a growing number of infections become resistant to antibiotic medications, it is becoming crucially important that providers not only practice antibiotic stewardship but also use effective antibiotics when they are needed.

Texas could be the site of the next large measles outbreak in the United States, according to a new study that highlights the low vaccination rates among schools there.

No one knows exactly why thousands of patients in dozens of states have contracted hepatitis A in recent years. In the absence of an explanation, public health officials are focusing on vaccination.

Three children in US Customs and Border Protection custody have died since December 2018, partially due to influenza. Now, the infectious disease community is rallying for vaccination for migrants in detention facilities.

DNA barcoding, an emerging technique for identifying fungal pathogens, from 2 regions could help speed up diagnosis and treatment, a new study found.

William Schaffner, MD, breaks down the new ACIP guideline recommendation, the pediatric benefit of PCV13 which drove the decision, and means by which it can improve clinical decisions surrounding vaccination.

Parents seeking medical exclusions for their children must now have their physician fill out a state form explaining specifically why the exemption is warranted.

Investigators in the first human trial of a MERS-CoV candidate report strong immune responses and no serious adverse events, advancing the vaccine candidate to phase 1/2a and phase 2 trials.

We're failing to make sure cultures are indicated properly in catheterized patients, which can lead to serious disruptions of care.

The NIH-funded study will evaluate experimental adjuvants AF03 and Advax-CpG55.2 over an 18-month study period.

Monica V. Mahoney, PharmD, discusses how shorter courses of therapy are just as effective as longer courses of therapy.

Leslie Tari, PhD, discusses the treatment and prevention of influenza.

An update for clinical providers.

The Ad26.ZEBOV, MVA-BN-Filo vaccine regimen will be evaluated in an open-label, single-arm study of 800 participants, including frontline health care workers.

The first step (prime) is to immunize with conventional vaccines through a needle in the arm. The second step (pull), is to apply an antibiotic cream that helps attract, T cells, to the site of virus growth.

The latest guidance on preparing for and responding to measles in your health care facility.